Improving Subunit Vaccines Against Tuberculosis For Pulmonary Delivery
Funder
National Health and Medical Research Council
Funding Amount
$635,320.00
Summary
Tuberculosis is an enormous health problem globally and remains a threat to Australia because of our proximity to high burden countries. The development of better vaccines against TB is crucial to reducing disease and preventing transmission. We shall develop and test new TB vaccines composed of a protective TB protein and immune-stimulating molecules in dry powder which can be safely delivered to the lungs. This respirable vaccine will be used to protect against TB and boost the effects of BCG.
Multistage Vaccines For The Prevention Of Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$884,290.00
Summary
Almost two million people die from tuberculosis (TB) each year. The current vaccine, BCG, is ineffective at controlling TB and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with novel delivery strategies to develop new TB vaccines. We will also determine the type of immune response needed to protect against TB, which will aid progression of vaccines into clinical trials.
Developing A Vaccine To Protect Against Hypervirulent Strains Of Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$536,850.00
Summary
Epidemic invasive GAS disease is associated with the emergence of the globally disseminated M1T1 clone and is linked to the mutation in the CovR/S regulator. This mutation leads to over- expression of SpyCEP and inhibits recruitment of neutrophils to the site of infection. Inclusion of an immunogenic fragment of SpyCEP into our current vaccine would enhance its efficacy and lead to the development of a vaccine with a wider coverage and better protective efficacy against hypervirulent GAS strains
New Candidate Vaccines To Prevent Tuberculosis: Preclinical Assessment Of Efficacy, Safety And Mechanism Of Protection
Funder
National Health and Medical Research Council
Funding Amount
$594,133.00
Summary
Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.
Group A streptococcus (GAS) is a bacteria that causes a wide range of disease in humans. GAS diseases are more common in Australias Indigenous population, and other health and economically disadvantaged groups than more affluent groups. In this study we will evaluate the effectiveness of novel vaccine candidates designed to prevent infection from all strains of GAS.
Novel Therapeutic And Preventive Strategies For Clostridium Difficile Infections.
Funder
National Health and Medical Research Council
Funding Amount
$508,556.00
Summary
The bacterium Clostridium difficile is the major cause of nosocomial diarrhoea in many countries, including Australia. More virulent isolates have recently emerged, leading to increased incidence and disease severity in many countries. This project will make a major contribution to our understanding of how these bacteria cause disease. Preventive or treatment measures based on these research findings will help to prevent or lessen the severity of any epidemics that occur in Australia.
Vaccinating Against Helicobacter Pylori-induced Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,088,714.00
Summary
Stomach cancer is the 3rd leading cause of cancer-related deaths. Most stomach cancers result from inflammation due to Helicobacter pylori infection. Most infections are treatable with antibiotics but this does not protect against cancers that develop before infection is diagnosed. Normal vaccine approaches aimed at this infection have been unsuccessful. We have identified a new approach for protecting against stomach cancer by preventing inflammation; this project aims to develop this vaccine.
Evolution Of Pertussis Epidemics And Effect Of Genotypes On Infection Outcomes And Immunisation
Funder
National Health and Medical Research Council
Funding Amount
$657,781.00
Summary
Pertussis, or whooping cough, is caused by Bordetella pertussis. Despite high vaccine coverage, the incidence of pertussis has increased substantially in recent years in Australia. One of the contributing factors is changes in the pertussis strains. This project will determine the genetic composition and virulence characteristics of epidemic strains in Australia and investigate the effect of these strains on disease severity and vulnerability of vaccinated individuals to infection.
Evaluation Of Haemophilus Haemolyticus As A Preventative Therapy For NTHi Disease
Funder
National Health and Medical Research Council
Funding Amount
$445,659.00
Summary
Middle ear infections are the most common reason for a child to be given antibiotics and undergo surgery. This project will investigate whether a harmless bacterium found in the respiratory tract of children can be used as a probiotic to prevent bacterial ear infections. Benefits from reducing ear infections include fewer children undergoing surgery, fewer GP visits and antibiotic prescriptions, less time off work for parents, reduced hearing loss in children, and improved educational outcomes.
Identification Of Novel Gonococcal Virulence Factors And Vaccine Antigens Based On Their Expression During Host Cell Contact And Their Role In Association, Invasion And Survival In Cervical Epithelia
Funder
National Health and Medical Research Council
Funding Amount
$371,922.00
Summary
The sexually transmitted infection gonorrhoea is a significant health problem worldwide. Control of gonorrhoea depends on the development of a vaccine due to the continuing increase of antibiotic resistance and the staggering outcomes of infection, including infertility and increased transmission of HIV. My research aims to discover new vaccine targets by identifying gonococcal proteins that are required for interaction with human cervical cells.